TG Therapeutics Surges to 476th in Daily Rankings with $180 Million Turnover

On April 2, 2025, TG Therapeutics (TGTX) saw a significant surge in trading volume, with a turnover of $180 million, marking a 142.02% increase from the previous day. This substantial rise placed TGTX at the 476th position in the daily stock market rankings, reflecting a notable uptick in investor interest. The stock price of TGTX rose by 5.48%.

Roche Holding AG's recent Phase 3 trial results for its multiple sclerosis drug, Ocrevus, have had a significant impact on the competitive landscape of MS treatments. The high-dose version of Ocrevus failed to meet its primary endpoint, leading to a positive response in the stock market for TG Therapeutics (TGTX). This development has shifted market dynamics, as Roche and Novartis had previously dominated the MS treatment market until TG Therapeutics received FDA approval for Briumvi in 2022. Despite the setback, Roche confirmed that the current dosage of Ocrevus remains effective in slowing the progression of multiple sclerosis.

Analysts have expressed optimism about TG Therapeutics' future prospects. Based on insights from seven analysts, the average 12-month target price for TGTX is $42.43, with estimates ranging from $10.00 to $55.00. This target price suggests a potential upside of 6.58% from the current trading price. The general sentiment from eight brokerage firms rates TGTX at an average of 2.1 on the recommendation scale, corresponding to an "Outperform" status. This reflects robust investor confidence, with the scale ranging from 1 indicating Strong Buy to 5 suggesting a Sell.